Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for Intellia Therapeutics (NTLA) over the last 7 years, with Q3 2025 value amounting to $115.9 million.

  • Intellia Therapeutics' Change in Acquisitions & Divestments fell 4193.56% to $115.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $778.6 million, marking a year-over-year decrease of 1738.94%. This contributed to the annual value of $1.1 billion for FY2024, which is 2027.0% up from last year.
  • Latest data reveals that Intellia Therapeutics reported Change in Acquisitions & Divestments of $115.9 million as of Q3 2025, which was down 4193.56% from $162.7 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Change in Acquisitions & Divestments peaked at $321.6 million during Q4 2024, and registered a low of $73.3 million during Q2 2021.
  • For the 5-year period, Intellia Therapeutics' Change in Acquisitions & Divestments averaged around $186.5 million, with its median value being $197.2 million (2023).
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first skyrocketed by 39796.84% in 2021, then tumbled by 4193.56% in 2025.
  • Quarter analysis of 5 years shows Intellia Therapeutics' Change in Acquisitions & Divestments stood at $94.6 million in 2021, then skyrocketed by 122.16% to $210.2 million in 2022, then decreased by 6.17% to $197.2 million in 2023, then soared by 63.08% to $321.6 million in 2024, then tumbled by 63.95% to $115.9 million in 2025.
  • Its last three reported values are $115.9 million in Q3 2025, $162.7 million for Q2 2025, and $178.3 million during Q1 2025.